Orphazyme prepares for USD 50m capital hunt after nightmare year

After a year that brought Orphazyme failed studies and a rejection from the FDA, the Copenhagen-based biotech firm is now planning to bring in USD 50m by issuing American Depositary Shares (ADSs).

Photo: Orphazyme/PR

Biotech business Orphazyme, which is based in Copenhagen, Denmark, is planning to raise USD 50m through an American Depositary Shares (ADSs) issuance, it reports in a press release.

The statement also reports that net proceeds from the ADS sales will be spent on the ongoing regulatory approval process for its main candidate arimoclomol, which is a treatment for the neurodegenerative disease, Niemann-Pick disease type C (NPC), in addition to the commercial launch should the drug be approved. The money will also be spent on "general corporate purposes," the press release reads.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs